CBIO vs ED · $491.3M cap vs P/E 18, rev $15.26B
Crescent Biopharma, Inc. (CBIO) versus Consolidated Edison Inc (ED) — a side-by-side from cached financials, not a winner call.
Crescent Biopharma, Inc. (CBIO) is a biotechnology company listed on NASDAQ.
Consolidated Edison Inc (ED) is a utilities - regulated electric company listed on US.
CBIO does not have a complete income-statement cache yet.
Latest reported ED revenue for 2024-12-31 was $15.26B. Net income was $1.82B. Revenue was up 4.0% from 2023-12-31 to 2024-12-31. ED currently screens at market cap $36.02B and trailing P/E 18.3.
CBIO currently screens at market cap $491.3M. ED currently screens at market cap $36.02B and trailing P/E 18.3.
Not investment advice. Open the CBIO and ED stock pages for the full models.
Not investment advice.